Behavioral Neurobiology of Psychedelic Drugs

  • Adam L. Halberstadt
  • Franz X. Vollenweider
  • David E. Nichols
Book

Part of the Current Topics in Behavioral Neurosciences book series (CTBN, volume 36)

Table of contents

  1. Front Matter
    Pages i-x
    PDF
  2. Chemistry and Structure–Activity Relationships of Psychedelics
    David E. Nichols
    Pages 1-43
  3. Erratum to: Phenomenology, Structure, and Dynamic of Psychedelic States
    Katrin H. Preller, Franz X. Vollenweider
    Pages 1-1
    PDF
  4. Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways
    Juan F. López-Giménez, Javier González-Maeso
    Pages 45-73
  5. Effects of Hallucinogens on Neuronal Activity
    L. Lladó-Pelfort, P. Celada, M. S. Riga, E. Troyano-Rodríguez, N. Santana, F. Artigas
    Pages 75-105
  6. Interactions of Hallucinogens with the Glutamatergic System: Permissive Network Effects Mediated Through Cortical Layer V Pyramidal Neurons
    Gerard J. Marek
    Pages 107-135
  7. The Effects of Hallucinogens on Gene Expression
    David A. Martin, Charles D. Nichols
    Pages 137-158
  8. Effect of Hallucinogens on Unconditioned Behavior
    Adam L. Halberstadt, Mark A. Geyer
    Pages 159-199
  9. Hallucinogens in Drug Discrimination
    Lisa E. Baker
    Pages 201-219
  10. Phenomenology, Structure, and Dynamic of Psychedelic States
    Katrin H. Preller, Franz X. Vollenweider
    Pages 221-256
  11. Serotonergic Hallucinogen-Induced Visual Perceptual Alterations
    Michael Kometer, Franz X. Vollenweider
    Pages 257-282
  12. New World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca
    Dennis McKenna, Jordi Riba
    Pages 283-311
  13. Experimental Psychosis Research and Schizophrenia—Similarities and Dissimilarities in Psychopathology
    Leo Hermle, Rainer Kraehenmann
    Pages 313-332
  14. A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD
    John H. Halpern, Arturo G. Lerner, Torsten Passie
    Pages 333-360
  15. Therapeutic Applications of Classic Hallucinogens
    Michael P. Bogenschutz, Stephen Ross
    Pages 361-391
  16. Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates
    Frederick S. Barrett, Roland R. Griffiths
    Pages 393-430

About this book

Introduction

This volume brings together the latest basic and clinical research examining the effects and underlying mechanisms of psychedelic drugs. Examples of drugs within this group include LSD, psilocybin, and mescaline. Despite their structural differences, these compounds produce remarkably similar experiences in humans and share a common mechanism of action.  Commonalities among the substances in this family are addressed both at the clinical and phenomenological level and at the basic neurobiological mechanism level. To the extent possible, contributions relate the clinical and preclinical findings to one another across species. The volume addresses both the risks associated with the use of these drugs and the potential medical benefits that might be associated with these and related compounds.

Keywords

MDMA entactogens hallucinogens psychedelics psychotomimetics

Editors and affiliations

  • Adam L. Halberstadt
    • 1
  • Franz X. Vollenweider
    • 2
  • David E. Nichols
    • 3
  1. 1.Department of PsychiatryUniversity of California San DiegoLa JollaUSA
  2. 2.Psychiatric University Hospital, Heffter Research Center ZurichUniversity of ZurichZurichSwitzerland
  3. 3.Division of Chemical Biology and Medicinal ChemistryUniversity of North CarolinaChapel HillUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-662-55880-5
  • Copyright Information Springer-Verlag GmbH Germany, part of Springer Nature 2018
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Biomedical and Life Sciences
  • Print ISBN 978-3-662-55878-2
  • Online ISBN 978-3-662-55880-5
  • Series Print ISSN 1866-3370
  • Series Online ISSN 1866-3389
  • About this book
Industry Sectors
Biotechnology
Consumer Packaged Goods
Pharma